Diana McKenzie
Diana McKenzie's purchase track record
Diana McKenzie has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/9/2024 | AGL | $16K | +59.4% | +1.8% | -0.8% |
| 11/25/2024 | AGL | $28K | +61.1% | -1.3% | -1.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Vertex Highlights Sickle Cell Gene Therapy and Hormone Disorder Expansion. Vertex Pharmaceuticals is advancing a gene therapy for sickle cell disease, which could broaden its treatment portfolio but faces access challenges. The company also signals a potential new growth area in hormone disorders, moving beyond cystic fibrosis. With earnings approaching, investors are watching how these developments affect the company’s outlook. The stock has risen above the market recently, reflecting positive sentiment.
Transaction History
| AGL | ▲ Buy | Grant | 2,133 | $0 | 6/2/2026 | View on chart |
| VRTX | ▲ Buy | Grant | 943 | $0 | 5/1/2026 | View on chart |
| VRTX | ▼ Sell | Other | 796 | — | 5/1/2026 | View on chart |
| AGL | ▲ Buy | Grant | 78,724 | $0 | 5/28/2025 | View on chart |
| VRTX | ▼ Sell | Other | 1,001 | — | 5/1/2025 | View on chart |
| VRTX | ▲ Buy | Grant | 796 | $0 | 5/1/2025 | View on chart |
| AGL | ▲ Buy | Open Market | 7,500 | $16K | 12/9/2024 | View on chart |
| AGL | ▲ Buy | Open Market | 12,500 | $28K | 11/25/2024 | View on chart |
| AGL | ▲ Buy | Grant | 32,119 | $0 | 5/29/2024 | View on chart |
| VRTX | ▲ Buy | Grant | 1,001 | $0 | 5/1/2024 | View on chart |
| VRTX | ▼ Sell | Other | 1,168 | — | 5/1/2024 | View on chart |
| VRTX | ▲ Buy | Grant | 1,168 | $0 | 5/1/2023 | View on chart |
| VRTX | ▼ Sell | Other | 1,449 | — | 5/1/2023 | View on chart |
| AGL | ▲ Buy | Grant | 5,622 | $0 | 4/14/2023 | View on chart |
| AGL | ▲ Buy | Grant | 1,078 | $0 | 2/17/2023 | View on chart |
| VRTX | ▲ Buy | Grant | 1,449 | $0 | 5/1/2022 | View on chart |
| VRTX | ▼ Sell | Other | 1,842 | — | 5/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Agilon Health Stock Moves Amid Peer Comparison
Recent market activity for Agilon Health has drawn attention to how its performance compares with other medical sector stocks this year. The company's stock is currently trading near a significant support level, which may be influencing investor sentiment. Analysts maintain a wide range of price targets, reflecting varying views on the company's future trajectory.
Agilon Health Stock Moves Amid Peer Comparison. Recent market activity for Agilon Health has drawn attention to how its performance compares with other medical sector stocks this year. The company's stock is currently trading near a significant support level, which may be influencing investor sentiment. Analysts maintain a wide range of price targets, reflecting varying views on the company's future trajectory.